Department of Anesthesiology, University of Michigan Health System, Ann Arbor, Michigan; the Department of Obstetrics and Gynecology, New York Medical College, Valhalla, New York; the Division for Heart Disease and Stroke Prevention and the Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia; and the Department of Anesthesiology, Critical Care, & Pain Medicine, Massachusetts General Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Obstet Gynecol. 2013 Dec;122(6):1288-94. doi: 10.1097/AOG.0000000000000021.
To define the frequency, risk factors, and outcomes of massive transfusion in obstetrics.
The State Inpatient Dataset for New York (1998-2007) was used to identify all delivery hospitalizations for hospitals that reported at least one delivery-related transfusion per year. Multivariable logistic regression analysis was performed to examine the relationship between maternal age, race, and relevant clinical variables and the risk of massive blood transfusion defined as 10 or more units of blood recorded.
Massive blood transfusion complicated 6 of every 10,000 deliveries with cases observed even in the smallest facilities. Risk factors with the strongest independent associations with massive blood transfusion included abnormal placentation (1.6/10,000 deliveries, adjusted odds ratio [OR] 18.5, 95% confidence interval [CI] 14.7-23.3), placental abruption (1.0/10,000, adjusted OR 14.6, 95% CI 11.2-19.0), severe preeclampsia (0.8/10,000, adjusted OR 10.4, 95% CI 7.7-14.2), and intrauterine fetal demise (0.7/10,000, adjusted OR 5.5, 95% CI 3.9-7.8). The most common etiologies of massive blood transfusion were abnormal placentation (26.6% of cases), uterine atony (21.2%), placental abruption (16.7%), and postpartum hemorrhage associated with coagulopathy (15.0%). A disproportionate number of women who received a massive blood transfusion experienced severe morbidity including renal failure, acute respiratory distress syndrome, sepsis, and in-hospital death.
Massive blood transfusion was infrequent, regardless of facility size. In the presence of known risk for receipt of massive blood transfusion, women should be informed of this possibility, should deliver in a well-resourced facility if possible, and should receive appropriate blood product preparation and venous access in advance of delivery.
: II.
定义产科大量输血的频率、风险因素和结局。
使用纽约州住院患者数据集(1998-2007 年),确定每年报告至少一次与分娩相关输血的医院的所有分娩住院情况。采用多变量逻辑回归分析,研究产妇年龄、种族和相关临床变量与大量输血的风险之间的关系,大量输血定义为记录 10 个或更多单位的血液。
每 10000 次分娩中就有 6 次发生大量输血,即使在最小的医疗机构也观察到这种情况。与大量输血有最强独立关联的危险因素包括异常胎盘(每 10000 次分娩 1.6 例,调整后的优势比[OR]为 18.5,95%置信区间[CI]为 14.7-23.3)、胎盘早剥(每 10000 次分娩 1.0 例,调整后的 OR 为 14.6,95%CI 为 11.2-19.0)、严重子痫前期(每 10000 次分娩 0.8 例,调整后的 OR 为 10.4,95%CI 为 7.7-14.2)和宫内胎儿死亡(每 10000 次分娩 0.7 例,调整后的 OR 为 5.5,95%CI 为 3.9-7.8)。大量输血最常见的病因包括异常胎盘(26.6%的病例)、子宫收缩乏力(21.2%)、胎盘早剥(16.7%)和与凝血功能障碍相关的产后出血(15.0%)。大量输血的女性中有相当一部分经历了严重的并发症,包括肾衰竭、急性呼吸窘迫综合征、败血症和院内死亡。
无论医疗机构的规模大小,大量输血都很少见。如果已知有接受大量输血的风险,应告知产妇这种可能性,如果可能,应在资源充足的医疗机构分娩,并在分娩前做好适当的血制品准备和静脉通路建立。
II。